Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27984466 | 0.85 | NUDT1 (0.41) | NUDT1BACE1S1PR1S1PR3S1PR4 | |
| SCHEMBL2235318 | 0.83 | S1PR1 (0.43) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL4663106 | 0.82 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL3846473 | 0.82 | S1PR1 (0.44) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL29381464 | 0.82 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL30418848 | 0.82 | S1PR1 (0.44) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL18671230 | 0.82 | S1PR1 (0.45) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL22504242 | 0.82 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL20863953 | 0.82 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL3906129 | 0.82 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021240547-A2 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORMS THEREOF | CIPLA LIMITED (IN) | 2021-12-02 | — | — | WO | disclosed |